HKD32.92
5.11% day before yesterday
Hong Kong, Aug 22, 10:08 am CET
ISIN
KYG970081173
Symbol
2269
Index

WuXi Biologics Stock price

HKD32.92
+4.92 17.57% 1M
+9.27 39.20% 6M
+15.36 87.47% YTD
+22.52 216.54% 1Y
-34.93 51.48% 3Y
-28.71 46.59% 5Y
+23.50 249.59% 10Y
+23.50 249.59% 20Y
Hong Kong, Closing price Fri, Aug 22 2025
+1.60 5.11%

Key metrics

Basic
Market capitalization
HKD127.5b
Enterprise Value
HKD119.4b
Net debt
positive
Cash
HKD13.7b
Shares outstanding
4.1b
Valuation (TTM | estimate)
P/E
30.5 | 28.3
P/S
5.8 | 5.4
EV/Sales
5.5 | 5.0
EV/FCF
-
P/B
2.6
Financial Health
Equity Ratio
73.4%
Return on Equity
8.0%
ROCE
12.2%
ROIC
11.9%
Debt/Equity
0.1
Financials (TTM | estimate)
Revenue
HKD21.9b | HKD23.6b
EBITDA
- | HKD8.3b
EBIT
HKD6.9b | HKD6.4b
Net Income
HKD4.6b | HKD4.7b
Free Cash Flow
-
Growth (TTM | estimate)
Revenue
17.2% | 16.1%
EBITDA
- | 21.6%
EBIT
64.1% | 20.8%
Net Income
59.4% | 29.5%
Free Cash Flow
-
Margin (TTM | estimate)
Gross
42.7%
EBITDA
- | 35.2%
EBIT
31.6%
Net
20.9% | 20.1%
Free Cash Flow
-
More
EPS
HKD1.1
FCF per Share
-
Short interest
-
Employees
13k
Rev per Employee
HKD1.6m
Show more

Is WuXi Biologics a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,015 stocks worldwide.

WuXi Biologics Stock Analysis

Unlock Scores for Free

Analyst Opinions

32 Analysts have issued a WuXi Biologics forecast:

23x Buy
72%
9x Hold
28%

Analyst Opinions

32 Analysts have issued a WuXi Biologics forecast:

Buy
72%
Hold
28%

Financial data from WuXi Biologics

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
21,872 21,872
17% 17%
100%
- Direct Costs 12,543 12,543
10% 10%
57%
9,329 9,329
29% 29%
43%
- Selling and Administrative Expenses 2,506 2,506
3% 3%
11%
- Research and Development Expense 835 835
3% 3%
4%
- -
-
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT 6,901 6,901
64% 64%
32%
Net Profit 4,577 4,577
59% 59%
21%

In millions HKD.

Don't miss a Thing! We will send you all news about WuXi Biologics directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

Wuxi Biologics (Cayman), Inc. is an investment holding company, which engages in the discovery, development and manufacture of biologics services. Its services include testing; clinical drug substance cGMP manufacture; commercial drug substance cGMP manufacture; drug product cGMP fill and finish; antibody drug conjugates; regulatory affairs; and technologies and platforms. The company was founded on May 24, 2010 and is headquartered in Wuxi, China.

Head office Cayman Islands
CEO Zhi Chen
Employees 12,575
Founded 2010
Website www.wuxibiologics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today